Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 5/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3717657 | 1.00 | HCRTR2 (0.54) | HCRTR2HCRTR1HSD11B1MGLLKDM5A | |
| SCHEMBL4245060 | 0.89 | HSD11B1 (0.61) | HCRTR2HCRTR1HSD11B1MGLLKDM5A | |
| SCHEMBL3661733 | 0.89 | HSD11B1 (0.61) | HCRTR2HCRTR1HSD11B1MGLLKDM5A | |
| SCHEMBL4238339 | 0.77 | CYP2C9 (0.60) | HSD11B1MGLLCYP2C9CYP2C19MAPK14 | |
| SCHEMBL3661780 | 0.77 | CYP2C9 (0.60) | HSD11B1MGLLCYP2C9CYP2C19MAPK14 | |
| SCHEMBL5390608 | 0.75 | MEN1 (0.58) | HSD11B1MGLLPARP1PARP2KMT2A | |
| SCHEMBL4251429 | 0.74 | HCRTR2 (0.52) | HCRTR2HCRTR1KDM5A | |
| SCHEMBL4251432 | 0.74 | HCRTR2 (0.52) | HCRTR2HCRTR1KDM5A | |
| SCHEMBL17856075 | 0.74 | HSD11B1 (0.54) | HSD11B1MGLLPARP1PARP2ALDH1A1 | |
| SCHEMBL8226203 | 0.72 | HCRTR2 (0.46) | HCRTR2HCRTR1HSD11B1KDM5ACACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2234999-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | HCRTR2 2/4885HCRTR1 1/4885HSD11B1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.